Clinical Drug Investigation

, Volume 16, Issue 5, pp 393–398 | Cite as

No Effect of Citalopram on Plasma Levels of Clozapine, Risperidone and their Active Metabolites in Patients with Chronic Schizophrenia

  • Angela Avenoso
  • Gabriella Facciolà
  • Maria Gabriella Scordo
  • Carmelo Gitto
  • Giuseppina Drago Ferrante
  • Aldo G. Madia
  • Edoardo Spina
Drug Interactions


Objective: The effect of citalopram on steady-state plasma concentrations of the newer antipsychotics clozapine and risperidone was studied in 15 schizophrenic patients with residual negative symptoms.

Methods: Eight patients stabilised on clozapine therapy (200 to 400 mg/day) and seven on risperidone (4 to 6 mg/day) received additional citalopram (40 mg/day) for 8 consecutive weeks.

Results: There were no significant changes in plasma concentrations of clozapine, risperidone and their active metabolites during the study period, suggesting that citalopram does not affect their metabolism. An improvement in negative symptomatology, as measured by the Scale for Assessment of Negative Symptoms, was observed in two patients in each group and the drug combination was well tolerated.

Conclusion: While controlled studies are needed to evaluate the clinical benefits of citalopram in chronic schizophrenia, our findings indicate that citalopram may be added to the therapy of patients on maintenance treatment with clozapine or risperidone.


Clozapine Fluoxetine Risperidone Fluvoxamine Chronic Schizophrenia 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Plasky P. Antidepressant usage in schizophrenia. Schizophr Bull 1991; 17: 649–57PubMedGoogle Scholar
  2. 2.
    Silver H, Nassar A. Fluvoxamine improves negative symptoms in treated chronic schizophrenia: an add-on double-blind, placebo controlled study. Biol Psychiatry 1992; 31: 698–704PubMedCrossRefGoogle Scholar
  3. 3.
    Spina E, De Domenico P, Ruello C, et al. Adjunctive fluoxetine in the treatment of negative symptoms in chronic schizophrenic patients. Int Clin Psychopharmacol 1994; 9: 281–5PubMedCrossRefGoogle Scholar
  4. 4.
    Lane RM. Pharmacokinetic drug interaction potential of selective serotonin reuptake inhibitors. Int Clin Psychopharmacol 1996; 11Suppl. 5: 31–61PubMedCrossRefGoogle Scholar
  5. 5.
    Sproule BA, Naranjo CA, Bremner KE, et al. Selective serotonin reuptake inhibitors and CNS drug interactions. A critical review of the evidence. Clin Pharmacokinet 1997; 33: 454–71PubMedCrossRefGoogle Scholar
  6. 6.
    Bertilsson L, Dahl M-L. Polymorphic drug oxidation: relevance to the treatment of psychiatric disorders. CNS Drugs 1996; 5: 200–23CrossRefGoogle Scholar
  7. 7.
    Goff D, Midha K, Brotman A, et al. Elevation of plasma concentrations of haloperidol after addition of fluoxetine. Am J Psychiatry 1991; 148: 790–2PubMedGoogle Scholar
  8. 8.
    Avenoso A, Spina E, Campo G, et al. Interaction between fluoxetine and haloperidol: pharmacokinetic and clinical implications. Pharmacol Res 1997; 35: 335–9PubMedGoogle Scholar
  9. 9.
    Ozdemir V, Naranjo CA, Herrmann N, et al. Paroxetine potentiates CNS side effects of perphenazine: contribution of cytochrome P450 2D6 inhibition in vivo. Clin Pharmacol Ther 1997; 62: 334–47PubMedCrossRefGoogle Scholar
  10. 10.
    Syvalahti EK, Taiminen T, Saarijarvi S, et al. Citalopram causes no significant alterations in plasma neuroleptic levels in schizophrenic patients. J Int Med Res 1997; 25: 24–32PubMedGoogle Scholar
  11. 11.
    Byerly MJ, DeVane CL. Pharmacokinetics of clozapine and risperidone: a review of recent literature. J Clin Psychopharmacol 1996; 16: 177–87PubMedCrossRefGoogle Scholar
  12. 12.
    Hiemke C, Weighmann H, Dahmen N, et al. Elevated serum levels of clozapine after addition of fluvoxamine. J Clin Psychopharmacol 1994; 14: 279–81PubMedCrossRefGoogle Scholar
  13. 13.
    Jerling M, Lindstrom L, Bondesson U, et al. Fluvoxamine inhibition and carbamazepine induction of the metabolism of clozapine: evidence from a therapeutic drug monitoring service. Ther Drug Monit 1994; 16: 368–74PubMedCrossRefGoogle Scholar
  14. 14.
    Centorrino F, Baldessarini RJ, Kando J, et al. Serum concentrations of clozapine and its major metabolites: effects of cotreatment with fluoxetine or valproate. Am J Psychiatry 1994; 151: 123–5PubMedGoogle Scholar
  15. 15.
    Centorrino F, Baldessarini RJ, Frankenburg F, et al. Serum levels of clozapine and norclozapine in patients treated with selective serotonin reuptake inhibitors. Am J Psychiatry 1996; 153: 820–2PubMedGoogle Scholar
  16. 16.
    Spina E, Avenoso A, Facciolà G, et al. Effect of fluoxetine on plasma concentrations of clozapine and its major metabolites in patients with schizophrenia. Int Clin Psychopharmacol 1998; 13: 141–5PubMedCrossRefGoogle Scholar
  17. 17.
    Taylor D, Ellison Z, Shaw LE, et al. Co-administration of citalopram and clozapine: effect on plasma clozapine levels. Int Clin Psychopharmacol 1998; 13: 19–21PubMedCrossRefGoogle Scholar
  18. 18.
    Andreasen NC. Scale for the assessment of negative symptoms (SANS). University of Iowa, Iowa, 1983Google Scholar
  19. 19.
    Avenoso A, Facciolà G, Campo GM, et al. Determination of clozapine, N-desmethylclozapine, and clozapine N-oxide in human plasma by reverse phase high-performance liquid chromatography with ultraviolet detection. J Chromatogr B Biomed Appl 1998; 714: 299–308CrossRefGoogle Scholar
  20. 20.
    Olesen OV, Linnet K. Simplified high-performance liquid Chromatographic method for determination of risperidone and 9-hydroxyrisperidone in serum from patients comedicated with other psychotropic drugs. J Chromatogr B Biomed Appl 1997; 698: 209–16CrossRefGoogle Scholar
  21. 21.
    Oyehaug E, Ostensen ET, Salvesen B. High-performance liquid Chromatographic determination of citalopram and four of its metabolites in plasma and urine samples from psychiatric patients. J Chromatogr B Biomed Appl 1984; 308: 199–208CrossRefGoogle Scholar
  22. 22.
    Andreasen NC. Scale for the assessment of positive symptoms (SAPS). University of Iowa, Iowa, 1984Google Scholar
  23. 23.
    Simpson GM, Angus JWS. Drug-induced extrapyramidal disorders. Acta Psychiatr Scand 1970; 212 Suppl.: 11–9CrossRefGoogle Scholar
  24. 24.
    Bertilsson L, Carrillo JA, Dahl ML, et al. Clozapine disposition covaries with the CYP1A2 activity determined by the caffeine test. Br J Clin Pharmacol 1994; 38: 471–3PubMedCrossRefGoogle Scholar
  25. 25.
    Linnet K, Olesen OV. Metabolism of clozapine by cDNA-expressed human cytochrome P450 enzymes. Drug Metab Dispos 1997; 25: 1379–82PubMedGoogle Scholar
  26. 26.
    Eiermann B, Engel G, Johansson I, et al. The involvement of CYP1A2 and CYP3A4 in the metabolism of clozapine. Br J Clin Pharmacol 1997; 44: 439–44PubMedCrossRefGoogle Scholar
  27. 27.
    Brosen K, Skielbo E, Rasmussen BB, et al. Fluvoxamine is a potent inhibitor of cytochrome P4501A2. Biochem Pharmacol 1993; 45: 1211–4PubMedCrossRefGoogle Scholar
  28. 28.
    Rasmussen BB, Maenpaa J, Pelkonen O, et al. Selective serotonin reuptake inhibitors and theophylline metabolism in human liver microsomes: potent inhibition by fluvoxamine. Br J Clin Pharmacol 1995; 39: 151–9PubMedCrossRefGoogle Scholar
  29. 29.
    Crewe HK, Lennard MS, Tucker GT, et al. The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 activity in human liver. Br J Clin Pharmacol 1992; 34: 262–5PubMedCrossRefGoogle Scholar
  30. 30.
    Kobayashi K, Yamamoto T, Chiba K, et al. The effects of serotonin reuptake inhibitors and their metabolites on Smephenytoin 4-hydroxylase activity in human liver microsomes. Br J Clin Pharmacol 1995; 40: 481–5PubMedCrossRefGoogle Scholar
  31. 31.
    Pies R. Extrapyramidal side effects with low-dose risperidone. Can J Psychiatry 1997; 42: 881PubMedGoogle Scholar
  32. 32.
    Salokongas RK, Saarijarvi S, Taiminen T, et al. Citalopram as an adjuvant in chronic schizophrenia: a double-blind placebo-controlled study. Acta Psychiatr Scand 1996; 94: 175–80CrossRefGoogle Scholar

Copyright information

© Adis International Limited 1998

Authors and Affiliations

  • Angela Avenoso
    • 1
  • Gabriella Facciolà
    • 1
  • Maria Gabriella Scordo
    • 1
  • Carmelo Gitto
    • 2
  • Giuseppina Drago Ferrante
    • 2
  • Aldo G. Madia
    • 2
  • Edoardo Spina
    • 1
    • 2
  1. 1.Institute of PharmacologyUniversity of MessinaMessinaItaly
  2. 2.Centers of Mental HealthMessinaItaly

Personalised recommendations